Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Published byΛάζαρος Κουντουριώτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Grant agencies and charitable foundations supporting Plan S."— Presentation transcript:

1 Figure 1 Grant agencies and charitable foundations supporting Plan S.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, Volume 40, Issue 27, 14 July 2019, Pages 2177–2179, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Grant agencies and charitable foundations supporting Plan S."

Similar presentations

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.

Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.

Similar presentations

Ads by Google